- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03623386
Effect of Mental Imagery Training on Brain Plasticity and Motor Function in Individuals With Parkinson's Disease
February 13, 2024 updated by: Yale University
Effect of Mental Imagery Training on Brain Plasticity and Motor Function in Individuals With Parkinson's Disease: A Functional MRI Investigation
Effect of Mental Imagery Training on Brain Plasticity and Motor Function in Individuals with Parkinson's Disease: A functional MRI investigation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This project will examine the effect of functional MRI-based neurofeedback on brain plasticity and motor performance in patients with Parkinson's Disease (PD).
Study Type
Interventional
Enrollment (Actual)
63
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sule Tinaz, MD, PhD
- Phone Number: 203-737-6158
- Email: sule.tinaz@yale.edu
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
38 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subjects with a diagnosis of idiopathic PD defined according to the UK Brain Bank diagnostic criteria and on a stable dopaminergic medication regimen will be included.
Exclusion Criteria:
- Age < 40 years
- Non-English speaking
- Pregnancy
- Breastfeeding
- Excessive alcohol consumption (> 7 drinks per week for women, > 14 drinks per week for men) or substance use
- History of a neurological disorder such as a brain tumor, stroke, central nervous system infection, multiple sclerosis, movement disorder (other than PD), or seizures
- History of schizophrenia, bipolar disorder, attention deficit disorder, or obsessive compulsive disorder
- History of head injury with loss of consciousness
- Metallic surgical implants or traumatically implanted metallic foreign bodies
- Inability to lie flat for about an hour
- Discomfort being in small, enclosed spaces
- Dementia (Montreal Cognitive Assessment score < 21)
- Depression (Beck Depression Inventory-II score > 19)
- Hoehn & Yahr stage > 3 (i.e., able to stand and walk, but not fully independent)
- Focal neurological findings on exam that suggest cerebral pathology other than that associated with parkinsonism
- Motor symptoms that could potentially introduce too much motion artifact in the imaging data (e.g., MDS-UPDRS resting tremor score > 1 in limbs, head/chin tremor, or dyskinesia by history or exam).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients with PD neurofeedback training
Patients will receive neurofeedback training.
|
PD-neurofeedback subjects will practice motor imagery in the MRI scanner and receive neurofeedback on their performance.
There will be a total of 10-12 neurofeedback sessions on two separate days.
Subjects will continue practicing motor imagery at home every day throughout the study period for 4-6 weeks.
|
Active Comparator: Patients with PD control
Patients will not receive neurofeedback training.
|
PD-control subjects will practice visual imagery (e.g., of scenery, objects, etc., but not of movement) in the MRI scanner and will not receive neurofeedback on their performance.
Subjects will continue practicing visual imagery at home every day throughout the study period for 4-6 weeks.
|
No Intervention: Patients with PD
Patients perform mental imagery (motor and visual aspects combined) in the MRI scanner without neurofeedback training.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Right Insula-dorsomedial Frontal Cortex Functional Connectivity Strength.
Time Frame: 4-6 weeks
|
The functional connectivity strength between the subjects' right insula and dorsomedial frontal cortex will be measured at baseline and post-intervention as each group of subjects engages in their respective imagery tasks.
Functional connectivity will be measured as the correlation value between the functional MRI signal time courses obtained from these two brain regions.
|
4-6 weeks
|
Change in Resting-state Functional Connectivity Between the Right Insula and Dorsomedial Frontal Cortex.
Time Frame: 4-6 weeks
|
We will obtain resting-state functional MRI scans from the PD-neurofeedback and PD-control groups at baseline and post-intervention to examine the changes in intrinsic functional connectivity between the right insula and dorsomedial frontal cortex.
Functional connectivity will be measured as the correlation value between the functional MRI signal time courses obtained from these two brain regions.
|
4-6 weeks
|
Change in Motor Impairment
Time Frame: Baseline and 4-6 weeks
|
We will administer the Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III (motor exam) at baseline and post-intervention to the PD-neurofeedback and PD-control groups to measure the change in motor impairment.
The MDS-UPDRS part III is a subscale that provides an objective assessment of motor impairment.
The scores range between 0-132.
Higher scores indicate more severe impairment.
|
Baseline and 4-6 weeks
|
Change in Motor Function
Time Frame: Baseline and 4-6 weeks
|
We will administer standard motor function tests (e.g., timed up and go, 5 times sit-to-stand, 360-degree turn) at baseline and post-intervention to the PD-neurofeedback and PD-control groups to measure the change in motor function.
The performance score on these tests is the time to complete the motor tasks.
Shorter time indicates better performance.
The motor function tests measure movement speed.
Timed up and go test measures (seconds) how fast one can stand up from a chair, walk 3 meters, turn, walk back to the chair and sit down again.
Five times sit-to-stand test measures (seconds) how fast one can stand up from a chair with arms crossed across the chest and sit back again 5 times in a row.
360-degree turn test measures (seconds) how fast one can turn around their own axis clockwise and counterclockwise.
The composite motor function score is the sum of the durations (seconds) of all three tests.
|
Baseline and 4-6 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Task-based Functional Connectivity
Time Frame: 1 day
|
In a group of PD patients who will not receive any intervention, we will collect functional MRI data during a mental imagery task with both motor and visual imagery components to investigate the functional connectivity between the motor and visual networks.
|
1 day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sule Tinaz, MD, Phd, Yale University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 10, 2018
Primary Completion (Actual)
September 16, 2022
Study Completion (Actual)
September 16, 2022
Study Registration Dates
First Submitted
July 27, 2018
First Submitted That Met QC Criteria
August 6, 2018
First Posted (Actual)
August 9, 2018
Study Record Updates
Last Update Posted (Estimated)
February 15, 2024
Last Update Submitted That Met QC Criteria
February 13, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2000023535
- 1K23NS099478-01A1 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on PD neurofeedback
-
Kowloon Hospital, Hong KongChinese University of Hong KongCompletedStroke | Cognitive ImpairmentHong Kong
-
University of Rhode IslandRecruitingNeurofeedbackUnited States
-
Insel Gruppe AG, University Hospital BernUniversity of BernRecruiting
-
University of OxfordWellcome TrustTerminated
-
Leiden University Medical CenterCompletedElevated EEG Theta/Beta Ratio
-
University of PittsburghRecruiting
-
Laureate Institute for Brain Research, Inc.CompletedDepression | AnxietyUnited States
-
National Cheng-Kung University HospitalMinistry of Science and Technology, TaiwanEnrolling by invitationHIV Infections | Poor Quality SleepTaiwan
-
University Hospital TuebingenGerman Research FoundationCompletedAttention Deficit Hyperactivity DisorderGermany
-
Laureate Institute for Brain Research, Inc.National Institute of General Medical Sciences (NIGMS)RecruitingDepressive Disorder, MajorUnited States